SGLT2 inhibitor tofogliflozin marketing changes hands in Japan
Japan’s Chugai Pharmaceutical (TYO: 4519) says that both brands of its selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) tofogliflozin hydrate will now be distributed by privately-held Kowa Company.
Under license agreements in 2012, tofogliflozin has been marketed by Kowa under the brand name Deberza tablets 20mg and by French major Sanofi’s (Euronext: SAN) Japanese unit under the brand name as Apleway tablets 20mg following regulatory approvals in 2014 for the indication of type 2 diabetes mellitus, explained Chugai, which is majority-owned by Swiss giant Roche (ROG: SIX).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze